LONDON (Reuters) - Two new targeted therapies for bowel cancer should not be used on Britain’s state-run health service, the country’s cost-effectiveness watchdog NICE said on Monday. The recommendation angered patient groups, since both Avastin and Erbitux are widely available in the United States and much of Europe.
